Why the study?
To experimentally evaluate the effect of Multilayer Flow Modulator device deployment in an abdominal aortic aneurysm model with and without an incorporated branch.
Does the Multilayer Flow Modulator (MFM) device reduce intra-aneurysmal flow velocity and vorticity while preserving incorporated branch flow in an experimental AAA model?
Population
Abdominal aortic aneurysm models with and without incorporated branch
Comparison
Models with vs without Multilayer Flow Modulator device
Design
Experimental in vitro study
Key result
The Multilayer Flow Modulator reduced average intra-aneurysmal flow velocity by 74.9-87.0% and enstrophy by 96.3-97.5% in in vitro AAA models while preserving incorporated branch perfusion.
Authors
Loading...
Hypothesis-generating for MFM in AAA; prospective human trials needed before clinical consideration.
Does the Multilayer Flow Modulator (MFM) device reduce intra-aneurysmal flow velocity and vorticity while preserving incorporated branch flow in an experimental AAA model?
The MFM device effectively reduces intra-aneurysmal flow velocity and vorticity while maintaining incorporated branch perfusion and pressure, providing an experimental basis for its potential to reduce type II endoleaks in AAA treatment.
Tupin et al. (2020) studied Abdominal Aortic Aneurysm (AAA). Multilayer Flow Modulator (MFM) vs. Untreated control model was evaluated on Intra-aneurysmal mean flow velocity and enstrophy. The Multilayer Flow Modulator reduced average intra-aneurysmal flow velocity by 74.9-87.0% and enstrophy by 96.3-97.5% in in vitro AAA models while preserving incorporated branch perfusion.